Gene Therapy and Immune Senescence View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2009-01-01

AUTHORS

Jian Chen , Hui-Chen Hsu , John D. Mountz

ABSTRACT

Gene therapy can be classified according to the vector used for gene therapy and the transgene that will be expressed as a result of the gene therapy. One consideration for gene therapy is that certain vectors have larger capacities than others to incorporate genes. The second consideration is the duration of therapy, which depends upon the immune response after delivery of the therapy. Therapy duration usually exhibits a reciprocal relationship to therapy immunogenicity. A third consideration is safety. This is related both to the immunogenicity and adverse effects of potential integration. These factors are shown in Table 1. Advances to enable gene integration with safety have been carried out using a “suicide” gene, such as thymidine kinase (TK) that can be upregulated to eliminate cells in which the transgene has integrated into an adverse position in the genome. More... »

PAGES

1629-1646

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4020-9063-9_76

DOI

http://dx.doi.org/10.1007/978-1-4020-9063-9_76

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007480986


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/10", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Technology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1004", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Biotechnology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA", 
          "id": "http://www.grid.ac/institutes/grid.265892.2", 
          "name": [
            "Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Jian", 
        "id": "sg:person.01144563407.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144563407.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA", 
          "id": "http://www.grid.ac/institutes/grid.265892.2", 
          "name": [
            "Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hsu", 
        "givenName": "Hui-Chen", 
        "id": "sg:person.01263522210.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263522210.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA", 
          "id": "http://www.grid.ac/institutes/grid.265892.2", 
          "name": [
            "Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mountz", 
        "givenName": "John D.", 
        "id": "sg:person.07550405624.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07550405624.18"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2009-01-01", 
    "datePublishedReg": "2009-01-01", 
    "description": "Gene therapy can be classified according to the vector used for gene therapy and the transgene that will be expressed as a result of the gene therapy. One consideration for gene therapy is that certain vectors have larger capacities than others to incorporate genes. The second consideration is the duration of therapy, which depends upon the immune response after delivery of the therapy. Therapy duration usually exhibits a reciprocal relationship to therapy immunogenicity. A third consideration is safety. This is related both to the immunogenicity and adverse effects of potential integration. These factors are shown in Table 1. Advances to enable gene integration with safety have been carried out using a \u201csuicide\u201d gene, such as thymidine kinase (TK) that can be upregulated to eliminate cells in which the transgene has integrated into an adverse position in the genome.", 
    "editor": [
      {
        "familyName": "Fulop", 
        "givenName": "Tamas", 
        "type": "Person"
      }, 
      {
        "familyName": "Franceschi", 
        "givenName": "Claudio", 
        "type": "Person"
      }, 
      {
        "familyName": "Hirokawa", 
        "givenName": "Katsuiku", 
        "type": "Person"
      }, 
      {
        "familyName": "Pawelec", 
        "givenName": "Graham", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4020-9063-9_76", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4020-9062-2", 
        "978-1-4020-9063-9"
      ], 
      "name": "Handbook on Immunosenescence", 
      "type": "Book"
    }, 
    "keywords": [
      "gene therapy", 
      "thymidine kinase", 
      "large capacity", 
      "potential integration", 
      "gene integration", 
      "adverse position", 
      "certain vector", 
      "third consideration", 
      "transgene", 
      "vector", 
      "duration of therapy", 
      "integration", 
      "second consideration", 
      "therapy duration", 
      "immune senescence", 
      "delivery", 
      "immune response", 
      "therapy", 
      "adverse effects", 
      "capacity", 
      "immunogenicity", 
      "advances", 
      "consideration", 
      "duration", 
      "safety", 
      "reciprocal relationship", 
      "suicide", 
      "genes", 
      "Table 1", 
      "cells", 
      "results", 
      "response", 
      "factors", 
      "kinase", 
      "senescence", 
      "effect", 
      "relationship", 
      "position", 
      "genome", 
      "therapy immunogenicity"
    ], 
    "name": "Gene Therapy and Immune Senescence", 
    "pagination": "1629-1646", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007480986"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4020-9063-9_76"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4020-9063-9_76", 
      "https://app.dimensions.ai/details/publication/pub.1007480986"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-01-01T19:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/chapter/chapter_64.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4020-9063-9_76"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4020-9063-9_76'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4020-9063-9_76'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4020-9063-9_76'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4020-9063-9_76'


 

This table displays all metadata directly associated to this object as RDF triples.

129 TRIPLES      23 PREDICATES      65 URIs      58 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4020-9063-9_76 schema:about anzsrc-for:10
2 anzsrc-for:1004
3 schema:author N23f77945680b41bba45a7cfe225cdc3f
4 schema:datePublished 2009-01-01
5 schema:datePublishedReg 2009-01-01
6 schema:description Gene therapy can be classified according to the vector used for gene therapy and the transgene that will be expressed as a result of the gene therapy. One consideration for gene therapy is that certain vectors have larger capacities than others to incorporate genes. The second consideration is the duration of therapy, which depends upon the immune response after delivery of the therapy. Therapy duration usually exhibits a reciprocal relationship to therapy immunogenicity. A third consideration is safety. This is related both to the immunogenicity and adverse effects of potential integration. These factors are shown in Table 1. Advances to enable gene integration with safety have been carried out using a “suicide” gene, such as thymidine kinase (TK) that can be upregulated to eliminate cells in which the transgene has integrated into an adverse position in the genome.
7 schema:editor N15bd79c2fdeb405bb6f07cebaf4a263e
8 schema:genre chapter
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf N0a80d62a33454aa8a1dd2366deceb27f
12 schema:keywords Table 1
13 advances
14 adverse effects
15 adverse position
16 capacity
17 cells
18 certain vector
19 consideration
20 delivery
21 duration
22 duration of therapy
23 effect
24 factors
25 gene integration
26 gene therapy
27 genes
28 genome
29 immune response
30 immune senescence
31 immunogenicity
32 integration
33 kinase
34 large capacity
35 position
36 potential integration
37 reciprocal relationship
38 relationship
39 response
40 results
41 safety
42 second consideration
43 senescence
44 suicide
45 therapy
46 therapy duration
47 therapy immunogenicity
48 third consideration
49 thymidine kinase
50 transgene
51 vector
52 schema:name Gene Therapy and Immune Senescence
53 schema:pagination 1629-1646
54 schema:productId Nadd3d908a6c7499ea7090cd1cd55b355
55 Ndf86439afb344d4dbc45b8d5f9631c28
56 schema:publisher Nfd36c920443c4339b7051bf8815c1199
57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007480986
58 https://doi.org/10.1007/978-1-4020-9063-9_76
59 schema:sdDatePublished 2022-01-01T19:26
60 schema:sdLicense https://scigraph.springernature.com/explorer/license/
61 schema:sdPublisher Ncd09e8e705b048a39ba1176a4110a9ab
62 schema:url https://doi.org/10.1007/978-1-4020-9063-9_76
63 sgo:license sg:explorer/license/
64 sgo:sdDataset chapters
65 rdf:type schema:Chapter
66 N0a80d62a33454aa8a1dd2366deceb27f schema:isbn 978-1-4020-9062-2
67 978-1-4020-9063-9
68 schema:name Handbook on Immunosenescence
69 rdf:type schema:Book
70 N15bd79c2fdeb405bb6f07cebaf4a263e rdf:first N930956b21f5a4a29aa00270e9d82091e
71 rdf:rest N245e8ce3a4384f82806bd07d30a79e5c
72 N23f77945680b41bba45a7cfe225cdc3f rdf:first sg:person.01144563407.49
73 rdf:rest Nd962c9d0af634973804d8eb9f4955a4f
74 N245e8ce3a4384f82806bd07d30a79e5c rdf:first N5e3afbf14c5046a8afad0551e8063116
75 rdf:rest Nd458e67240e24623b399029e607ff17b
76 N36933c0280b94648bf475b103e00e38d rdf:first Nb05917cadafa4a049d664631f2fd7358
77 rdf:rest rdf:nil
78 N5e3afbf14c5046a8afad0551e8063116 schema:familyName Franceschi
79 schema:givenName Claudio
80 rdf:type schema:Person
81 N6a64deef0a5144e9bd38d7fd6e704bc2 rdf:first sg:person.07550405624.18
82 rdf:rest rdf:nil
83 N8c26f77ee32c4bb0bb2db249089ee8ab schema:familyName Hirokawa
84 schema:givenName Katsuiku
85 rdf:type schema:Person
86 N930956b21f5a4a29aa00270e9d82091e schema:familyName Fulop
87 schema:givenName Tamas
88 rdf:type schema:Person
89 Nadd3d908a6c7499ea7090cd1cd55b355 schema:name dimensions_id
90 schema:value pub.1007480986
91 rdf:type schema:PropertyValue
92 Nb05917cadafa4a049d664631f2fd7358 schema:familyName Pawelec
93 schema:givenName Graham
94 rdf:type schema:Person
95 Ncd09e8e705b048a39ba1176a4110a9ab schema:name Springer Nature - SN SciGraph project
96 rdf:type schema:Organization
97 Nd458e67240e24623b399029e607ff17b rdf:first N8c26f77ee32c4bb0bb2db249089ee8ab
98 rdf:rest N36933c0280b94648bf475b103e00e38d
99 Nd962c9d0af634973804d8eb9f4955a4f rdf:first sg:person.01263522210.53
100 rdf:rest N6a64deef0a5144e9bd38d7fd6e704bc2
101 Ndf86439afb344d4dbc45b8d5f9631c28 schema:name doi
102 schema:value 10.1007/978-1-4020-9063-9_76
103 rdf:type schema:PropertyValue
104 Nfd36c920443c4339b7051bf8815c1199 schema:name Springer Nature
105 rdf:type schema:Organisation
106 anzsrc-for:10 schema:inDefinedTermSet anzsrc-for:
107 schema:name Technology
108 rdf:type schema:DefinedTerm
109 anzsrc-for:1004 schema:inDefinedTermSet anzsrc-for:
110 schema:name Medical Biotechnology
111 rdf:type schema:DefinedTerm
112 sg:person.01144563407.49 schema:affiliation grid-institutes:grid.265892.2
113 schema:familyName Chen
114 schema:givenName Jian
115 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144563407.49
116 rdf:type schema:Person
117 sg:person.01263522210.53 schema:affiliation grid-institutes:grid.265892.2
118 schema:familyName Hsu
119 schema:givenName Hui-Chen
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263522210.53
121 rdf:type schema:Person
122 sg:person.07550405624.18 schema:affiliation grid-institutes:grid.265892.2
123 schema:familyName Mountz
124 schema:givenName John D.
125 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07550405624.18
126 rdf:type schema:Person
127 grid-institutes:grid.265892.2 schema:alternateName Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA
128 schema:name Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA
129 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...